Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Shares Acquired by Primecap Management Co. CA

Key Points

• Primecap Management Co. CA increased its holdings in Immunocore Holdings PLC by 0.4%, acquiring an additional 10,100 shares, bringing its total to approximately 2,678,650 shares worth $79.5 million.
• Immunocore reported $0.10 earnings per share for the latest quarter, significantly surpassing the consensus estimate of -$0.35, and revenue of $125.13 million, a 33.6% increase year-over-year.
• Analyst ratings for Immunocore show a general consensus of a "Moderate Buy" with an average price target of $58.89, reflecting strong bullish sentiment despite the stock's recent decline.

Primecap Management Co. CA lifted its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 0.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,678,650 shares of the company's stock after buying an additional 10,100 shares during the quarter. Primecap Management Co. CA owned approximately 5.35% of Immunocore worth $79,476,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Barclays PLC increased its position in Immunocore by 2,044.0% during the fourth quarter. Barclays PLC now owns 20,625 shares of the company's stock valued at $608,000 after acquiring an additional 19,663 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Immunocore during the first quarter valued at $225,000. Legal & General Group Plc increased its position in Immunocore by 17.3% during the fourth quarter. Legal & General Group Plc now owns 136,875 shares of the company's stock valued at $4,038,000 after acquiring an additional 20,163 shares during the last quarter. GAMMA Investing LLC increased its position in Immunocore by 3,318.1% during the first quarter. GAMMA Investing LLC now owns 19,107 shares of the company's stock valued at $5,670,000 after acquiring an additional 18,548 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Immunocore by 1.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock valued at $64,533,000 after acquiring an additional 29,832 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Trading Up 0.4%

Shares of NASDAQ IMCR traded up $0.12 during trading on Monday, hitting $32.09. 82,619 shares of the company were exchanged, compared to its average volume of 337,863. Immunocore Holdings PLC Sponsored ADR has a 12-month low of $23.15 and a 12-month high of $39.33. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.86 and a current ratio of 5.89. The company has a fifty day moving average price of $34.15 and a 200-day moving average price of $31.23. The firm has a market capitalization of $1.61 billion, a PE ratio of -80.18 and a beta of 0.77.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. The firm had revenue of $130.65 million for the quarter, compared to analyst estimates of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. Immunocore's revenue was up 30.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.23) EPS. As a group, equities research analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IMCR shares. Wall Street Zen cut shares of Immunocore from a "buy" rating to a "hold" rating in a report on Saturday. HC Wainwright restated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Monday, June 2nd. JPMorgan Chase & Co. cut their price target on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a report on Monday, April 14th. Oppenheimer upped their price target on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Immunocore in a report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Immunocore currently has an average rating of "Hold" and an average price target of $58.00.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.